NCT03636438View on ClinicalTrials.gov

Long Term Follow Up to Evaluate DTX301 in Adults With Late-Onset OTC Deficiency

Active, not recruitingOBSERVATIONAL
Enrollment

11

Participants

Timeline

Start Date

August 30, 2018

Primary Completion Date

December 31, 2029

Study Completion Date

December 31, 2029

Conditions
Ornithine Transcarbamylase (OTC) Deficiency
Interventions
OTHER

No Intervention

No Intervention

Trial Locations (9)

10029

Icahn School of Medicine, New York

15706

Hospital Clinico Universitario de Santiago, Santiago de Compostela

44106

University Hospital Cleveland Medical Center/Case Western Reserve University, Cleveland

48903

Hospital Universitario de Cruces. Servicio de Pediatria, Barakaldo

69677

Hopital Femme Mere Enfant, Bron

80045

The Children's Hospital Colorado, Aurora

02115

Boston Children's Hospital, Boston

T2E 7Z4

M.A.G.I.C. Clinic, Calgary

B15 2TH

Queen Elizabeth Hospital, Department of Endocrinology, Birmingham

All Listed Sponsors
lead

Ultragenyx Pharmaceutical Inc

INDUSTRY

NCT03636438 - Long Term Follow Up to Evaluate DTX301 in Adults With Late-Onset OTC Deficiency | Biotech Hunter | Biotech Hunter